Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › PA › Norristown › NPI 1205872041
Lab

Quest Diagnostics Clinical Laboratories INC

Quest Diagnostics Clinical Laboratories INC was paid $22.72M by Medicaid between Jan 2018 and Dec 2024, across 342 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 47% of everything it billed.

33Billing provider infoQUEST DIAGNOSTICS CLINICAL LABORATORIES INC
NORRISTOWN, PA 19403
33aNPI1205872041assigned 06/21/2006
33bProvider typeClinical Medical Laboratory
28Total paid$22.72M
24GClaims1,819,376
24DCodes billed342
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Clinical Medical Laboratory providers in Pennsylvania

Rank by total paid#8 of 95
Median peer was paid$153K
This provider vs. median149×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Auditor's notes

Automated statistical signals. Not evidence of fraud — how these are computed.

Entity ProliferationAuthorized official TIMMERMAN, LEAH controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service

Paid by month

$0$1.0M$2.0M$3.0M2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
2018167,709$1.63M
2019131,936$1.39M
2020425,408$7.29M
20211,090,234$12.35M
2022311$4K
20231,766$23K
2024incomplete2,012$43K
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 47% 134,837 121,718 $10.78M
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 5.9% 42,018 33,446 $1.33M
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 4.6% 28,280 22,519 $1.06M
80050 General health panel 2.5% 19,557 19,288 $559K
80061 Lipid panel 2.3% 99,044 96,439 $522K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 2.1% 62,025 59,176 $483K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 2.1% 61,788 58,966 $480K
80053 Comprehensive metabolic panel 1.8% 102,004 97,593 $402K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 1.5% 28,996 28,282 $352K
84443 Thyroid stimulating hormone (TSH) 1.5% 60,339 58,453 $348K
81420 Fetal chromosomal aneuploidy genomic sequence analysis panel 1.5% 2,944 2,919 $342K
86480 1.5% 11,567 10,999 $330K
330 more codes
81220 CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants 1.3% 3,631 $291K
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe 1.3% 29,758 $289K
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 1.2% 35,072 $282K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 1.1% 11,581 $245K
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types 1.0% 15,197 $230K
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer <1% 17,972 $205K
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 92,222 $191K
86803 <1% 26,176 $176K
83036 Hemoglobin; glycosylated (A1C) <1% 71,885 $164K
80081 <1% 3,939 $144K
87536 <1% 3,484 $121K
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms <1% 10,287 $111K
87086 Culture, bacterial; quantitative colony count, urine <1% 32,087 $93K
82607 <1% 15,809 $92K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 4,636 $89K
84153 <1% 10,347 $88K
86769 <1% 2,567 $76K
87522 Neg quan hep c or qual rna <1% 4,202 $72K
82728 <1% 15,512 $70K
80074 <1% 4,220 $68K
87340 <1% 14,759 $65K
87902 <1% 646 $65K
84439 <1% 20,953 $60K
87799 <1% 23,062 $59K
87512 <1% 9,299 $53K
85027 <1% 24,973 $53K
86003 <1% 1,883 $52K
82746 <1% 10,150 $50K
80048 Basic metabolic panel (calcium, ionized) <1% 15,546 $49K
86360 <1% 2,569 $48K
86592 <1% 35,991 $46K
82652 <1% 5,248 $45K
84702 <1% 6,896 $44K
84403 <1% 4,176 $43K
82248 <1% 15,368 $43K
83970 <1% 3,022 $43K
82043 <1% 19,228 $42K
82570 <1% 21,919 $41K
86787 <1% 5,689 $41K
83540 <1% 15,628 $39K
84146 <1% 3,932 $38K
87088 <1% 13,905 $38K
88142 <1% 4,867 $36K
83655 <1% 12,945 $35K
86235 <1% 1,648 $35K
36415 Collection of venous blood by venipuncture <1% 79,408 $35K
83021 <1% 3,883 $33K
83516 <1% 3,311 $31K
86618 <1% 2,619 $30K
83550 <1% 14,084 $29K
86762 <1% 3,596 $29K
81329 <1% 2,869 $28K
86706 <1% 5,474 $27K
84481 <1% 3,186 $27K
86038 <1% 5,311 $26K
82784 <1% 3,648 $26K
81001 <1% 27,013 $26K
86317 <1% 3,203 $24K
82105 <1% 4,143 $24K
87081 <1% 10,518 $24K
86704 <1% 3,942 $24K
86696 <1% 3,028 $23K
87186 <1% 7,522 $22K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed <1% 257 $21K
86708 <1% 3,331 $21K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed <1% 3,339 $20K
87070 <1% 7,358 $20K
83001 <1% 3,397 $20K
87077 <1% 7,148 $19K
84402 <1% 1,896 $19K
86695 <1% 2,889 $18K
80164 <1% 1,949 $17K
82670 <1% 1,890 $16K
83735 <1% 6,804 $16K
86617 <1% 857 $16K
86665 <1% 973 $16K
84436 <1% 5,493 $16K
87901 <1% 224 $16K
83013 <1% 1,184 $15K
80076 <1% 4,488 $15K
83002 <1% 2,634 $15K
86780 <1% 3,144 $14K
85610 <1% 10,824 $14K
86800 <1% 1,741 $13K
84480 <1% 3,197 $12K
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B <1% 72 $12K
88141 <1% 3,136 $12K
87480 <1% 970 $12K
87660 <1% 946 $11K
86735 <1% 1,328 $11K
86140 <1% 8,797 $11K
85652 <1% 10,697 $11K
84703 <1% 2,604 $11K
87510 <1% 731 $10K
86147 <1% 1,050 $10K
86376 <1% 2,422 $10K
88112 <1% 447 $10K
82950 <1% 4,976 $10K
81003 <1% 11,125 $9K
86160 <1% 1,369 $9K
87150 <1% 639 $9K
83525 <1% 1,988 $9K
86850 <1% 2,921 $9K
84479 <1% 3,406 $9K
87900 <1% 224 $9K
86361 <1% 998 $9K
86431 <1% 3,491 $8K
84154 <1% 1,679 $8K
82627 <1% 1,287 $8K
84550 <1% 4,465 $8K
86146 <1% 1,104 $8K
86200 <1% 1,564 $8K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 205 $8K
86765 <1% 1,448 $8K
86225 <1% 1,448 $7K
82785 <1% 1,317 $7K
83880 <1% 733 $7K
88312 <1% 117 $7K
83690 <1% 2,596 $6K
88342 <1% 417 $6K
86255 <1% 1,137 $6K
84425 <1% 1,428 $6K
87906 <1% 146 $6K
86705 <1% 806 $6K
86664 <1% 626 $6K
82977 <1% 2,160 $6K
85730 <1% 3,415 $6K
84100 <1% 2,977 $6K
87209 <1% 806 $5K
84460 <1% 3,732 $5K
80178 <1% 1,160 $5K
86900 <1% 3,378 $5K
86901 <1% 3,352 $5K
82677 <1% 314 $5K
86359 <1% 548 $5K
84144 <1% 951 $5K
87625 <1% 475 $5K
82550 <1% 1,933 $5K
85041 <1% 2,827 $5K
84165 <1% 1,068 $5K
85018 <1% 4,779 $5K
84270 <1% 695 $4K
87517 <1% 485 $4K
88304 <1% 284 $4K
82947 <1% 3,401 $4K
84156 <1% 3,614 $4K
84450 <1% 2,967 $4K
87338 <1% 608 $4K
87147 <1% 3,144 $4K
86334 <1% 483 $4K
82274 <1% 1,760 $4K
81596 <1% 506 $3K
86039 <1% 843 $3K
83615 <1% 1,433 $3K
82150 <1% 1,481 $3K
83520 <1% 1,495 $3K
82533 <1% 593 $3K
81401 <1% 335 $3K
83020 <1% 1,468 $3K
80197 <1% 897 $3K
82951 <1% 884 $3K
87427 <1% 613 $3K
87324 <1% 252 $3K
83993 <1% 373 $3K
87449 <1% 254 $3K
82378 <1% 562 $2K
86707 <1% 351 $2K
87481 <1% 123 $2K
82565 <1% 1,563 $2K
85014 <1% 3,843 $2K
88341 <1% 127 $2K
87177 <1% 811 $2K
81511 <1% 76 $2K
87350 <1% 398 $2K
87255 <1% 241 $2K
83498 <1% 455 $2K
87045 <1% 667 $2K
84445 <1% 407 $2K
85045 <1% 1,456 $2K
80156 <1% 198 $2K
86304 <1% 303 $2K
80069 <1% 628 $2K
83721 <1% 601 $2K
84681 <1% 247 $2K
86008 <1% 81 $2K
82310 <1% 1,334 $2K
84134 <1% 298 $2K
87101 <1% 833 $2K
84305 <1% 254 $2K
80055 <1% 189 $2K
86777 <1% 245 $1K
85660 <1% 824 $1K
83921 <1% 377 $1K
84432 <1% 194 $1K
87329 <1% 255 $1K
86812 <1% 217 $1K
86021 <1% 353 $1K
84520 <1% 1,244 $1K
86644 <1% 214 $1K
87650 <1% 187 $1K
87102 <1% 247 $1K
87075 <1% 410 $1K
86709 <1% 261 $1K
82103 <1% 219 $1K
86141 <1% 266 $1K
84466 <1% 232 $1K
82542 <1% 220 $1K
86593 <1% 722 $1K
80177 <1% 216 $1K
84075 <1% 907 $1K
85048 <1% 2,110 $1K
82040 <1% 1,375 $1K
87046 <1% 649 $1K
82247 <1% 875 $1K
82465 <1% 1,031 $1K
82024 <1% 102 $986.60
85613 <1% 353 $944.58
84630 <1% 372 $939.36
82390 <1% 301 $872.03
85004 <1% 1,150 $860.63
80051 <1% 314 $820.36
82164 <1% 134 $807.27
86355 <1% 59 $796.57
81025 <1% 592 $788.44
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 39 $782.89
82955 <1% 452 $778.38
84166 <1% 157 $738.86
86645 <1% 111 $696.43
87205 <1% 507 $687.19
82952 <1% 841 $682.41
83718 <1% 487 $619.27
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc <1% 12 $615.72
84155 <1% 976 $598.85
86336 <1% 322 $590.03
86778 <1% 164 $585.40
82330 <1% 180 $536.32
83090 <1% 90 $536.08
86162 <1% 66 $523.63
84590 <1% 363 $486.98
87220 <1% 682 $484.46
87107 <1% 246 $483.51
86308 <1% 144 $481.22
85379 <1% 260 $450.41
81015 <1% 648 $443.89
86702 <1% 151 $440.64
84478 <1% 173 $438.28
87106 <1% 97 $424.49
85007 <1% 231 $420.66
82525 <1% 78 $419.60
87493 <1% 25 $385.16
80175 <1% 48 $382.75
82985 <1% 131 $376.44
86701 <1% 150 $346.98
82088 <1% 29 $343.92
84132 <1% 443 $316.74
82668 <1% 106 $316.11
86341 <1% 190 $314.41
86870 <1% 119 $277.05
84295 <1% 486 $274.83
86301 <1% 83 $274.80
85049 <1% 1,173 $267.10
82157 <1% 192 $225.70
86060 <1% 83 $203.85
87040 <1% 70 $194.37
82575 <1% 72 $187.41
81243 <1% 209 $186.53
86880 <1% 124 $185.99
83883 <1% 41 $179.58
80299 <1% 12 $179.00
82787 <1% 12 $164.62
86357 <1% 13 $161.05
84207 <1% 69 $158.21
80185 <1% 48 $157.43
84378 <1% 130 $150.59
82435 <1% 473 $140.77
86335 <1% 27 $139.23
82610 <1% 46 $136.75
87272 <1% 17 $131.11
83010 <1% 57 $128.59
82374 <1% 150 $117.33
86886 <1% 75 $104.01
86300 <1% 27 $85.23
85246 <1% 163 $81.36
82672 <1% 12 $74.85
89051 <1% 28 $70.71
85245 <1% 119 $68.90
82140 <1% 12 $59.57
81241 <1% 100 $59.36
82397 <1% 14 $52.44
80165 <1% 36 $49.69
87184 <1% 38 $46.62
89060 <1% 16 $45.61
85240 <1% 125 $44.43
89055 <1% 14 $43.28
87076 <1% 12 $35.46
83014 <1% 56 $34.83
85247 <1% 25 $28.22
87206 <1% 17 $24.38
84244 <1% 50 $20.95
84484 <1% 12 $17.56
82705 <1% 13 $14.55
86337 <1% 42 $11.00
80365 <1% 41 $10.52
80361 <1% 41 $10.52
86682 <1% 29 $10.20
83835 <1% 12 $9.20
85384 <1% 12 $8.82
80354 <1% 163 $7.51
99001 <1% 1,726 $1.98
81257 0% 183 $0.00
80348 0% 70 $0.00
88262 0% 26 $0.00
80372 0% 64 $0.00
80346 0% 47 $0.00
G0479 Drug test(s), presumptive, any number of drug classes; any number of devices or procedures by instrumented chemistry analyzers utilizing immunoassay, enzyme assay, tof, maldi, ldtd, desi, dart, ghpc, gc mass spectrometry), includes sample validation when performed, per date of service 0% 14 $0.00
80362 0% 66 $0.00
80360 0% 64 $0.00
80373 0% 65 $0.00
88230 0% 13 $0.00
87563 0% 12 $0.00
84446 0% 12 $0.00
82626 0% 119 $0.00
81240 0% 44 $0.00
80368 0% 67 $0.00
81229 0% 25 $0.00
80349 0% 39 $0.00
80371 0% 64 $0.00
80358 0% 49 $0.00
92004 Ophthalmological services: medical examination and evaluation, comprehensive, new patient 0% 35 $0.00
G0103 Prostate cancer screening; prostate specific antigen test (psa) 0% 27 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialTIMMERMAN, LEAH (SR. VICE PRESIDENT)
Parent organizationQUEST DIAGNOSTICS INCORPORATED
Same official

Other billing entities under TIMMERMAN, LEAH

Full network →
ProviderLocationPaid
Unilab CorporationWest Hills, CA$668.50M
Quest Diagnostics IncorporatedClifton, NJ$637.74M
Quest Diagnostics LLC IlWood Dale, IL$429.84M
Quest Diagnostics Clinical Laboratories INCIrving, TX$276.76M
Labone LLCLenexa, KS$212.28M
Quest Diagnostics Clinical Laboratories INCTucker, GA$211.13M
Quest Diagnostics Clinical Laboratories INCMiramar, FL$197.58M
Labone of Ohio INCCincinnati, OH$167.17M
Unilab CorporationSacramento, CA$141.24M
Quest Diagnostics Incorporated MDBaltimore, MD$121.81M
Quest Diagnostics IncorporatedLas Vegas, NV$59.32M
Quest Diagnostics LLC IlSchaumburg, IL$50.71M
Quest Diagnostics Clinical Laboratories INCTampa, FL$49.99M
Quest Diagnostics Nichols Institute, INC.Chantilly, VA$46.91M
Quest Diagnostics Nichols InstituteSan Juan Capistrano, CA$39.93M
Specialty Laboratories INCWest Hills, CA$16.76M
Quest Diagnostics Clinical Laboratories INCDenver, CO$14.27M
Quest Diagnostics Clinical Laboratories INCHouston, TX$8.76M
Med Fusion, LLCLewisville, TX$4.17M
Quest Diagnostics Clinical Laboratories INCMaryland Heights, MO$2.98M

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.